Chemomab Therapeutics Ltd DRC (CMMB) — Cash Flow-to-Debt Ratio
Chemomab Therapeutics Ltd DRC (CMMB) has a Cash Flow-to-Debt Ratio of -7.59x as of December 2025, meaning its operating cash flow of $-11.22 Million could theoretically repay -8% of its total liabilities ($1.48 Million) in one year. See CMMB net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Chemomab Therapeutics Ltd DRC Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Chemomab Therapeutics Ltd DRC across 11 annual periods. Also explore CMMB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Chemomab Therapeutics Ltd DRC (2015–2025)
Year-by-year debt coverage analysis for Chemomab Therapeutics Ltd DRC. For market capitalisation and broader financial context, see Chemomab Therapeutics Ltd DRC (CMMB) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -7.59x | $-11.22 Million | $1.48 Million | ▼ -68.3% |
| 2024 | -4.51x | $-15.46 Million | $3.43 Million | ▲ +1.3% |
| 2023 | -4.57x | $-23.55 Million | $5.15 Million | ▼ -54.0% |
| 2022 | -2.97x | $-20.29 Million | $6.84 Million | ▲ +30.8% |
| 2021 | -4.29x | $-12.38 Million | $2.89 Million | ▲ +43.9% |
| 2020 | -7.65x | $-12.80 Million | $1.67 Million | ▼ -124.4% |
| 2019 | -3.41x | $-16.51 Million | $4.85 Million | ▲ +29.0% |
| 2018 | -4.80x | $-14.18 Million | $2.96 Million | ▼ -50.7% |
| 2017 | -3.18x | $-8.58 Million | $2.70 Million | ▼ -100.8% |
| 2016 | -1.59x | $-3.74 Million | $2.36 Million | ▲ +70.6% |
| 2015 | -5.38x | $-7.38 Million | $1.37 Million | — |